Frequency Therapeutics, up until now a biotech startup in stealth mode, has announced that they will begin clinical trials for hearing loss in 2017. Nick Paul Taylor recently interviewed Jeffrey Karp where Karp made this exclusive announcement. Frequency is going after the inner ear opportunity, but, in its short life to date, has kept a very low profile and revealed little about its technology or R&D strategy. That is about to change. “The company is set to begin clinical trials next year for hearing loss,” announced Karp.
Frequency Therapeutics has solved a key bottleneck in bringing stem cell programming to patients by “harnessing rapidly translatable small molecule combinations that selectively target entrenched stem cells in the body”. The Atlantic reported last month that “patent filings indicate (Frequency) has been developing ways to induce supporting cells to multiply, then become hair cells, using a notch inhibitor. The procedure would involve releasing the drug locally, perhaps as a foam or using a tube in the tympanic membrane to send doses into the middle ear.”
For the full interview with Karp download the complete report by journalist Nick Paul Taylor here: “Convergence in Boston: How multidisciplinary R&D is driving bench-to-bedside breakthroughs”. No email or registration is required.
We hope you enjoy Nick’s in-depth report. You can catch up with Jeffrey Karp’s newest discoveries and research at Biotech Week Boston's Cell and Gene Therapy Bioprocessing and Commercialization event this October. Jeffrey's talk is entitled "MSCs on steroids".
Share this article with your social network, just click below to share now!